Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6199932 | Ophthalmology | 2014 | 8 Pages |
Abstract
Fluocinolone acetonide implant therapy was reasonably cost-effective compared with systemic therapy for individuals with unilateral intermediate, posterior, or panuveitis but not for those with bilateral disease. These results do not apply to the use of implant therapy when systemic therapy has failed or is contraindicated. Should the duration of implant effect prove to be substantially >3 years or should large changes in therapy pricing occur, the cost-effectiveness of implant versus systemic therapy would need to be reevaluated.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
The Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group The Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Elizabeth A. PhD, Janet T. PhD, MPH, John H. MD, PhD, Alyce E. MPH, Lea T. PhD, Jennifer E. MD, PHD,